Public Market Listing
2552HKEX
Live quotes, historical charts, and market capitalization for Hua Medicine are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
Dorzagliatin(Huatangning) | Phase 3 | GlucokinaseSmall molecule | Type 2 Diabetes |
| Phase 1 | GlucokinaseSmall molecule | Type 2 Diabetes |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (4)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-H1 | $30M | $9.1M | $143M | — | report ↗ |
Hua Medicine reported revenue of $30M, up 110.2% YoY, R&D spend of $9.08M, down 45.5% YoY, and cash and equivalents of $142.79M for H1 2025.
Figures only: this period's report disclosed no narrative text
View 3 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-H1 | $14M | $17M | $184M | — | report ↗ |
| 2023-H1 | $10M | $10M | $122M | — | report ↗ |
| 2022-H1 | $0 | $11M | $88M | — | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $69M | $20M | $156M | — | report ↗ |